Malaysia has emerged as a major investment destination for biotech companies. The Malaysian biotech market posted high growth last year and is expected to do the same in next few years. Rich biodiversity, availability of low cost human resources and strong government efforts are some of the reasons that have boosted growth in the market. According to our new research report “Emerging Biotech Sector in Malaysia”, the biotech market in Malaysia is expected to grow at a CAGR of around 21% during 2010-2012.
We have studied the Malaysian biotech market by breaking it into three segments - healthcare biotech, agriculture biotech and industrial biotech. Each of these segments has been extensively covered in the report, giving in-depth analysis of the current and future market trends along with valuable data of past trends. Our report also provides a complete overview of regulatory environment for the biotech market.
Our report has found that increasing prevalence of diseases and rising exports of drugs from Malaysia are driving growth in the healthcare biotechnology market. This segment holds the highest potential for growth and will post the fastest growth rate among all the three segments. Besides, the country’s expertise in agriculture sector will give strong impetus to the growth of this segment in near future whereas surging exports of biofuels and palm oil will boost the industrial biotech segment. Moreover, our report also provides a complete overview of restraints that are blocking growth in the industry coupled with certain useful recommendations, which will be useful for both government and clients in future prospects.
The report studies the current development process and its effects on various segments of the industry. The research study gives detailed statistical and analytical information of macroeconomic indicators, key drivers and restraints. It also contains brief overview of government initiatives and key industry players that will help clients to draw up market strategies and assess areas of opportunity in the Malaysian biotech market.
